AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: LDR recurrence requires HDR follow-up. Low meeting demand leads to many open-mic Qs.
Topics Discussed
Focal HIFU therapy recurs as 3+3 in gland – which group to attend?; our military chaplain is stable but needs VA help; Frank very happy with AnCan’s GU med onc match; treating LDR brachy recurrence with HDR and SBRT; seeking next line of systemic treatment that’s not chemo or PSMA driven; spot RT for skull Mx; low tech swamp cooler hangs around the neck; old ivermectin/fenbendazole chestnut booted; 6x Pluvicto successfully completed; strategy for next chemo session; oxybutynin for hot flashes; E2 patch does not cause leg DVT; germline Gent questions need for counseling
Chat
Bob Schwartz, USN, Venice, FL sent: 3:45 PM
Frank, you help as much as you get help. Don’t ever doubt how much we appreciate you.
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Many tasty tips this week… our fave – clinical trials DON’T cover all costs
Topics Discussed
Liquid biopsies and biomarkers; Bispecific T-Cell Engagers (BITE) for TP53+RB1 Gent; is it time to test for small cell? – Provider doesn’t think so; dry mouth from denosumab/Xgeva – not quite, that’s ONJ – great dental health discussion; Reel Recovery takes his mind off seeking HT break; germline negative, but should T3b Gent stop HT after 9 months; the 2 Davids discuss trials managing oligoMx lightly; clinical trials often don’t cover all costs; our first Long Game man goes onto mono daro with 6 months NCI grace; Dr. E orders more tests to guide HT treatment – and suggests Good Patch for hot flashes; don’t worry yet about ‘morphing’ tests; PPI can elevate chromogranin; hypersensitivity to docetaxel demands dose adjustment; better GU doc on Florida Gulf Coast
Chat
Larry in AK sent: 5:13 PM
I will seek circulating tumor cell analysis searching for evolutionary changes in my cancer over time. Still in its infancy as a tool
Danny Lankford (Minnesota) sent: 5:29 PM
My wife and I are using Open Evidence. https://www.openevidence.com/ but you need an NPI (provider ID) to access it. It’s been amazing to help me along on my journey.
AnCan – Rick sent: 5:44 PM
oxybutynin -ditropan
Alfredo in Wimberley sent: 5:44 PM
OXYBUTYNIN (ox i BYOO ti nin) treats symptoms of an overactive bladder, such as loss of bladder control or frequent need to urinate. It works by relaxing muscles in the bladder. It belongs to a group of medications called antispasmodics. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. COMMON BRAND NAME(S): Ditropan XL
Danny Lankford (Minnesota) sent: 5:45 PM
same here on the venlafaxine 37.5mg for me and my mouth is dry as can be
I’m taking 2.5 mg of oxybutynin once a day, in the evening when I take my Apalutamide. Still get warm and sweat, but has taken the intense feeling of a hot flash away.
Another good mtg., have to go, see everyone next week.
Jann Nielsen sent: 6:35 PM
Great meeting. Have to go.
Luther sent: 6:43 PM
Good thing I’m seeing her on Wed. then
Frank Ciambra sent: 6:49 PM
I didnt hear a thing larry
Larry in AK sent: 6:51 PM
There are organizations that re-distribute prescription drugs. It is illegal, but some prosecutors shy away from prosecuting humanitarian bending” of the law.
Alfredo in Wimberley sent: 6:51 PM
I have to leave, best regards to one one and all!
Matt sent: 7:01 PM
evening fella! I’ll follow up. Cheers 😉
Bruce Schrimpf sent: 7:03 PM
Thanks for the information about Dr. Stish writing an article! I have had a long day and will call it a night.
A relatively new year, new guidelines, and new tools for prostate cancer screening and monitoring.
In recent months, the AUA updated its 2023 guidelines specifically for early detection of prostate cancer (https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guideline). Along with those guidelines, two other organizations have updated or developed additional tools that are beneficial to all men, regardless of where they are on the prostate cancer journey (or even those not yet on a journey).
Consider them collectively as an introduction to screening (NCCN), an AS-focused source (ASPI), and a comprehensive guide for early-stage prostate cancer.
I would not consider any of them as a standalone product for all the information a man might need. The NCCN guidelines are focused on screening and are relatively basic. ASPI’s product is focused on AS, but some may find the scope and scale of information a bit overwhelming without someone to advise and assist them. The appendix at the end of the pamphlet would be exceedingly useful for anyone beginning their prostate cancer journey. Finally, the AUA guidelines are broader and developed more for urologists.
AnCan frequently recommends second opinions on prostate cancer and genitourinary (GU) pathology slides – whether it be from biopsy, surgery or another protocol. Our recommended providers are:
Active Surveillance Prostate Cancer Video Chat, May 13th, 2026
AnCan is grateful to the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics, and Foundation Medicine.
Active Surveillance (AS) for low-risk prostate cancer involves unique challenges compared to other treatments. This online support group is designed for men and their caregivers who are currently on or considering AS. We hold four meetings monthly, recording only the second and fourth sessions. Our discussions cover a wide range of topics, including anxiety management, biopsy experiences, and the decision-making process around continuing or discontinuing AS. Newcomers are given priority to share their experiences, so we encourage you to join us.
Eric- Atlanta 8:29 PM
BPH ASPI video Dr. Casey Dauw: https://aspatients.org/meeting/the-abcs-of-bph/
Eric- Atlanta 8:30 PM
Ancan Special Presentation: It Ain’t Your Grandpa’s BPH: https://ancan.org/special-presentation-it-aint-your-grandpas-bph/
Andy Douglas, FL 8:40 PM
Standard Medicare Coverage Criteria (all must be met) Medicare covers Aquablation once per patient when: prostate volume is 30–150 cc confirmed by transrectal ultrasound (TRUS), IPSS score greater than or equal to 12, maximum urinary flow rate less than or equal to15 mL/s with voided volume greater than 125 cc, and there has been failure or intolerance of at least 3 months of conventional therapy (such as alpha-blockers or 5-ARIs). The procedure must use an FDA-approved device
Rob Wood 8:42 PM
Rob Wood – Maine– aquablation questions to Mike Williams woodsinmaine@gmail.com
BJ Kap 8:59 PM
thanks guys great discussion have a good night
Eric- Atlanta 9:10 PM
Benign Prostatic Hypertrophy (BPH) Morgan McDowell, DNP, APRN, WHNP-BC, AGPCNP-BC: https://grandroundsinurology.com/benign-prostatic-hypertrophy-bph/?_hsmi=381422106&fbclid=IwZXh0bgNhZW0CMTEAc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHicfwgnaFklEBjKzeyZafooENJ-llAD_2V-GZKdLpAKoPZvT4jXRibNOyO-y_aem_x0ohp35PKH7dhukcwFD2Tg
Mike Thompson 9:15 PM
Thanks everyone- great discussion tonight. Good night.
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Configuring your own treatment path for slowly recurring oligo-metastasis brings us to gynecomastia.
Topics Discussed
Younger Newbie asks what else after triplet protocol; older Newbie Vet with low grade recurrence and sickle cell trait; another triplet Newbie needs a GU MO after Cleveland Clinic fails him; salvage RT with no HT; capivasertib added to GUNS trial protocol; can we figure how to get SBRT + a little Pluvicto?; good discussion on gynecomastia; fatigue begs the Q… how long on HT??; Dr Wassersug delivers his E2 pitch; 2nd opinion confirms doublet but what’s the right salvage RT field.
Chat
AnCan – Rick sent: 3:03 PM
GoTo Support 877 582 701
To call in by phone dial 646 749 3129 then 222-583-973
